lifestyle.thedishh.com

Author: VANDA PHARMACEUTICALS INC

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

March 3, 2026
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

February 26, 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

February 25, 2026
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia – A New Chemical Entity Opening New Horizons in Psychiatric Innovation

February 20, 2026
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

February 7, 2026
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

January 8, 2026
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

December 30, 2025
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

December 15, 2025
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

December 12, 2025